JP2023543898A5 - - Google Patents
Info
- Publication number
- JP2023543898A5 JP2023543898A5 JP2023520059A JP2023520059A JP2023543898A5 JP 2023543898 A5 JP2023543898 A5 JP 2023543898A5 JP 2023520059 A JP2023520059 A JP 2023520059A JP 2023520059 A JP2023520059 A JP 2023520059A JP 2023543898 A5 JP2023543898 A5 JP 2023543898A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- shtg
- fpl
- fcs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087095P | 2020-10-02 | 2020-10-02 | |
| US63/087,095 | 2020-10-02 | ||
| PCT/US2021/052001 WO2022072244A1 (en) | 2020-10-02 | 2021-09-24 | Methods for reducing apociii expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543898A JP2023543898A (ja) | 2023-10-18 |
| JP2023543898A5 true JP2023543898A5 (enExample) | 2024-10-02 |
Family
ID=80950871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520059A Pending JP2023543898A (ja) | 2020-10-02 | 2021-09-24 | Ａｐｏｃｉｉｉ発現を減少させるための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240033280A1 (enExample) |
| EP (1) | EP4221720A4 (enExample) |
| JP (1) | JP2023543898A (enExample) |
| KR (1) | KR20230079394A (enExample) |
| CN (1) | CN116348125A (enExample) |
| AU (1) | AU2021353849A1 (enExample) |
| BR (1) | BR112023004012A2 (enExample) |
| IL (1) | IL300882A (enExample) |
| MX (1) | MX2023003855A (enExample) |
| WO (1) | WO2022072244A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2024097861A1 (en) * | 2022-11-02 | 2024-05-10 | Ionis Pharmaceuticals, Inc. | Methods for modulating complement factor b expression |
| KR20250173600A (ko) | 2023-03-17 | 2025-12-10 | 옥시토프 파마 비.브이. | 항-포스포콜린 항체 및 그 사용 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| DK2956176T3 (en) * | 2013-02-14 | 2018-08-27 | Ionis Pharmaceuticals Inc | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS |
| CN107405358A (zh) * | 2015-02-27 | 2017-11-28 | Ionis制药公司 | 调节脂肪代谢障碍群体中的载脂蛋白c‑iii(apociii)表达 |
| PL4119569T3 (pl) * | 2015-11-06 | 2024-11-18 | Ionis Pharmaceuticals, Inc. | Sprzężone związki antysensowne do zastosowania w terapii |
-
2021
- 2021-09-24 US US18/247,567 patent/US20240033280A1/en active Pending
- 2021-09-24 JP JP2023520059A patent/JP2023543898A/ja active Pending
- 2021-09-24 EP EP21876250.8A patent/EP4221720A4/en active Pending
- 2021-09-24 IL IL300882A patent/IL300882A/en unknown
- 2021-09-24 KR KR1020237013301A patent/KR20230079394A/ko active Pending
- 2021-09-24 CN CN202180066569.6A patent/CN116348125A/zh active Pending
- 2021-09-24 AU AU2021353849A patent/AU2021353849A1/en active Pending
- 2021-09-24 MX MX2023003855A patent/MX2023003855A/es unknown
- 2021-09-24 BR BR112023004012A patent/BR112023004012A2/pt unknown
- 2021-09-24 WO PCT/US2021/052001 patent/WO2022072244A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543898A5 (enExample) | ||
| US10376533B2 (en) | Compositions and methods for treating viral infections | |
| JP2688113B2 (ja) | 多発性硬化症の治療のための置換アデニン誘導体を含む薬学的組成物 | |
| JP2019511491A5 (enExample) | ||
| JP2017532982A (ja) | Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体 | |
| JP2026041749A5 (enExample) | ||
| JP2024037841A5 (enExample) | ||
| JP2018126141A5 (enExample) | ||
| BR112020018209A2 (pt) | Composições farmacêuticas, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e para tratar ou prevenir um coronavírus humano, coronavírus sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus da chicungunha, vírus ross river, rsv, vírus influenza a, vírus influenza b, vírus tacaribe, vírus pichinde, vírus junin, vírus da febre lassa, vírus da cariomeningite linfocitária, vírus da febre rift valley, vírus punta toro, vírus lacrosse, vírus maporal, vírus heartland, e vírus da síndrome de trombocitopenia de febre severa, poliovírus, vírus de coxsackie, infecção de norovírus ou enterovírus em um paciente | |
| JPH10507635A (ja) | 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用 | |
| JP2019088329A5 (enExample) | ||
| JP2002522552A (ja) | Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| CN114533739A (zh) | 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用 | |
| CN104955458A (zh) | 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法 | |
| JP2021511072A5 (enExample) | ||
| JP2020528910A5 (enExample) | ||
| RU2020127049A (ru) | Модуляторы экспрессии dnm2 | |
| JP2011515357A5 (enExample) | ||
| US6432924B1 (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
| JP2899292B2 (ja) | Ｂ型肝炎の抗ウイルス剤による治療方法 | |
| JP2025504017A5 (enExample) | ||
| AU732120B2 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
| CN1312254A (zh) | 新的核苷 | |
| CN110573620B (zh) | 血癌治疗剂 |